Secondary objective of the expansion cohorts phase
non-irradiated lesions
SECONDARY
The secondary objectives will be determined by the recommended scheme of administration.
To evaluate the progression-free survival (PFS) following SBRT, atezolizumab, and tiragolumab combinationTo evaluate the long-term safety of SBRT, atezolizumab, and tiragolumab antibodies combinationTo evaluate the overall survival (OS) following SBRT, atezolizumab, and tiragolumab combinationTo evaluate the overall response rate (ORR) and non-progression rate (NPR) following SBRT, atezolizumab and tiragolumab combinationTo evaluate the duration of response (DOR) and non-progression duration (NPD) following SBRT, atezolizumab and tiragolumab combinationTo evaluate the abscopal effect (non-irradiated lesions volume variation).